General Atlantic’s Centessa Pharmaceuticals CNTA Stock Holding History

General Atlantic’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.8M	Sell	1,354,830 -4,762,885	-78%	-$122M	2.5%	9
2025 Q4	$153M	Sell	6,117,715 -3,564,103	-37%	-$90.3M	5.33%	8
2025 Q3	$235M	Hold	9,681,818	–	–	7.05%	7
2025 Q2	$127M	Hold	9,681,818	–	–	3.51%	8
2025 Q1	$139M	Hold	9,681,818	–	–	4.67%	6
2024 Q4	$162M	Hold	9,681,818	–	–	5.77%	5
2024 Q3	$155M	Hold	9,681,818	–	–	4.4%	6
2024 Q2	$87.4M	Hold	9,681,818	–	–	2.75%	9
2024 Q1	$109M	Hold	9,681,818	–	–	2.54%	10
2023 Q4	$77.1M	Hold	9,681,818	–	–	1.11%	11
2023 Q3	$62.6M	Hold	9,681,818	–	–	0.97%	17
2023 Q2	$59.9M	Hold	9,681,818	–	–	0.94%	16
2023 Q1	$37.3M	Hold	9,681,818	–	–	0.43%	21
2022 Q4	$30M	Hold	9,681,818	–	–	0.4%	22
2022 Q3	$38.9M	Hold	9,681,818	–	–	0.46%	19
2022 Q2	$47.1M	Hold	9,681,818	–	–	0.62%	18
2022 Q1	$86.8M	Hold	9,681,818	–	–	0.79%	12
2021 Q4	$109M	Hold	9,681,818	–	–	0.84%	14
2021 Q3	$162M	Buy	9,681,818 +8,181,818	+545%	+$169M	0.95%	12
2021 Q2	$33.3M	Buy	+1,500,000	New	+$35.3M	0.24%	14

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

General Atlantic's CNTA Position: Q1 2026 in Review

General Atlantic reduced its Centessa Pharmaceuticals (CNTA) stake by 78% in Q1 2026, selling an estimated $122M and leaving 1,354,830 shares worth $53.8M. The position accounts for 2.5% of the portfolio, ranked #9.

General Atlantic first reported a position in CNTA in Q2 2021 and has held it in 20 quarters since. The position peaked at $235M in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

General Atlantic held 1,354,830 shares of Centessa Pharmaceuticals worth $53.8M as of Q1 2026.
General Atlantic sold 4,762,885 Centessa Pharmaceuticals shares in Q1 2026, an estimated $122M.
Centessa Pharmaceuticals made up 2.5% of General Atlantic's portfolio in Q1 2026, its #9 holding.
General Atlantic first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
General Atlantic's Centessa Pharmaceuticals position peaked at $235M in Q3 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on General Atlantic's 13F filing for Q1 2026, filed 15 May 2026.